Company Alert
USU Software

Results Initial View: Advance payments drag on results

HIGHLIGHTS

- Mixed start to the year
- Sales guidance raised

Mixed start to the year: In Q1/17 USU posted a convincing result on the sales side, up 11.4% y-o-y to EUR 18.9m, also due to the first-time consolidation of unitB which was acquired at the beginning of the year. Thanks to unitB, the Service unit surged by 43.4% to EUR 5.0m, while the Product unit disappointed with growth of 3.2% to EUR 13.9m. The key reason here is likely to have been license revenues, which declined by 14.3% to EUR 2.6m. The reasons the company provided were stronger demand for SaaS rather than license versions (maintenance/SaaS segment sales: +9.7%) and delayed license deals. With its software solutions, USU operates in a large-client environment, which has a positive impact on the volume of individual deals, but brings with it correspondingly complex approval cycles on the customer side. This year USU is moving up a gear in terms of international expansion and is taking on additional staff and pushing sales and marketing activities with the key objective of developing its international business. The lack of high-margin license revenues and additional advance expenses for the international business squeezed adjusted EBIT to EUR 0.7m (-49.6%).

Sales guidance raised: As a result of the acquisition of the French company EASYTRUST in May (cf. Alert on 5 May 2017), the company has raised its sales target from the previous level of between EUR 83m and EUR 88m to between EUR 86m and EUR 91m (LBBWe: EUR 88.1m). On the earnings side, no positive impetus is expected, as further investments are to be made in the product portfolio. The previous guidance for adjusted EBIT was thus confirmed at EUR 10m to EUR 11.5m. For 2017, USU is expecting a strong HY2, which is set to benefit from the advance payments made in the first six months. In our view, this appears realistic, but is associated with higher risk.

<table>
<thead>
<tr>
<th>in EUR m</th>
<th>Q1/2017</th>
<th>LBBW E</th>
<th>Q1/2017</th>
<th>yoy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>18.9</td>
<td>19.0</td>
<td>17.0</td>
<td>+11.4%</td>
</tr>
<tr>
<td>EBIT adj.</td>
<td>0.7</td>
<td>1.5</td>
<td>1.4</td>
<td>-49.6%</td>
</tr>
<tr>
<td>EPS (in EUR)</td>
<td>0.04</td>
<td>0.13</td>
<td>0.12</td>
<td>-65.4%</td>
</tr>
</tbody>
</table>

Source: USU, LBBW Research

---

FOR DISCLAIMER AND IMPORTANT DISCLOSURES PLEASE SEE APPENDIX-1
Appendix-1

Analytic's Certification
All of the views expressed in this research report accurately reflect the research analyst's personal views regarding the Subject Company. No part of analyst compensation was, is or will be, directly or indirectly related to the specific recommendations or views expressed in this research report.

Disclosures

Important Disclosures Required by Regulators

1) LBBW or an associated enterprise of LBBW supports the company in the market by entering buy or sell orders.
2) LBBW or an associated enterprise of LBBW has made an agreement on the production of financial analyses relating to the issuer or its financial instruments.
3) LBBW together with its affiliates is making a market in the company's securities.

Please Note
This research report and the information contained therein is furnished and has been prepared solely for information purposes. It is not intended to be an inducement to engage in investment activity. It is furnished for your private information with the express understanding, which recipient acknowledges, that it is not an offer, recommendation or solicitation to buy, hold or sell, an invitation to subscribe for or purchase, or a means by which any security may be offered or sold.

LBBW does not accept any liability for the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions or the result obtained from the use of such information. The information in this report has been obtained from sources believed to be reliable. LBBW cannot verify such information, however, and because of the possibility of human or mechanical error by the sources, LBBW or others, no representation is made that the information contained in this report is accurate in all material respects or complete. The statements contained herein are statements of our non-binding opinion, not statement of fact or recommendations to buy hold or sell any securities. Changes to assumptions may have a material impact on any performance detailed. Historic information on performance is not indicative of future performance. LBBW may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and LBBW is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. This report is intended only for and directed to persons sufficiently expert to understand the risks involved, namely market professionals. This publication does not replace personal consultancy. Prior to taking any investment decision you should contact your independent investment adviser for further and more up-to-date information on specific investment opportunities and for individual investment advice, regarding the appropriateness of investing in any securities or investment strategies discussed in this report.

Any security referred to therein may involve a high degree of risk, which may include principal, interest rate, index, currency, credit, political, liquidity, time value, commodity and market risk and is not suitable for all investors. The securities may experience sudden and large falls in their value causing losses equal to the original investment when that investment is realized. Any transaction entered into is in reliance only upon your judgment as to both financial, suitability and risk criteria. LBBW does not hold itself out to be an advisor in these circumstances, nor does any of its staff have the authority to do so.

Detailed information on the valuation, the valuation methods and the assumptions underlying them in accordance with Commission Delegated Regulation 2016/958 Article 4 (1) c) and the notes to Commission Delegated Regulation 2016/958 Article 4 (1) e) can be found at https://www.lbbw-research.de/publicdisclaimer. Updated information in accordance with Commission Delegated Regulation 2016/958 Article 6 (3) can be found at https://www.lbbw-research.de/publicdisclaimer.

United Kingdom
This document is issued in the United Kingdom by LBBW, London Branch. LBBW is authorised by the Bundesanstalt für Finanzdienstleistungsaufsicht (the “BaFin”).

This document and the information contained in it constitutes a financial promotion for the purposes of the Financial Services and Markets Act 2000 and the rules of the Financial Services Authority (the “FSA”). To the extent that this document is issued in the United Kingdom, it is directed exclusively at persons who are professional clients or
eligible counterparties for the purposes of the FSA’s Handbook of Rules and Guidance. The products and investment services to which this document relate are only available to the persons referred to above and other persons should not act or rely on it. Moreover, any investment or service to which this document relates is not intended for retail clients and will not be made available to retail clients.

This document is impartial investment research. This document has no regard to the specific investment objectives, financial need or situation or needs of any specific recipient and the investments discussed in this document may not be suitable for all recipients.

LBBW, London Branch has effective organisational and administrative arrangements set up for the prevention and avoidance of conflicts of interest with respect to research recommendations, including information barriers. A copy of LBBW’s investment research and conflict of interest policy is available on request from www.lbbw.de/lbbwde/1000005283-en.html

### LBBW Research Rating-Systematics (absolute share rating system)

<table>
<thead>
<tr>
<th>Rating</th>
<th>Definition</th>
<th>Percentage of companies within this rating category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buy:</td>
<td>Based on a time horizon of up to 12 months, we recommend that investors buy the stock.</td>
<td>33,2%</td>
</tr>
<tr>
<td>Sell:</td>
<td>Based on a time horizon of up to 12 months, we recommend that investors sell the stock.</td>
<td>6,3%</td>
</tr>
<tr>
<td>Hold:</td>
<td>We take a neutral view on the stock and, based on a time horizon of up to 12 months, do not recommend either a Buy or Sell.</td>
<td>60,5%</td>
</tr>
<tr>
<td>Under review:</td>
<td>The rating is currently updated.</td>
<td>0,0%</td>
</tr>
<tr>
<td>Suspended:</td>
<td>The evaluation of the company is currently not feasible.</td>
<td>0,0%</td>
</tr>
</tbody>
</table>